PHP
SLNO

Parkman Healthcare Partners’s Soleno Therapeutics SLNO Stock Holding History

Parkman Healthcare Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$2.95M – 103
2023
Q3 		$2.95M Buy
+100,000
New +$605K 0.54% 56

Other funds holding SLNO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Parkman Healthcare Partners's SLNO Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Soleno Therapeutics (SLNO) in Q4 2023, closing a stake of 100,000 shares — an estimated $2.95M sold.

Parkman Healthcare Partners first reported a position in SLNO in Q3 2023 and held it in 1 quarter. The position peaked at $2.95M in Q3 2023. 76 funds tracked by Wall St. Rank hold SLNO as of Q4 2023.

  • Parkman Healthcare Partners reported no remaining Soleno Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 100,000 Soleno Therapeutics shares in Q4 2023, an estimated $2.95M.
  • Parkman Healthcare Partners first reported a position in Soleno Therapeutics in Q3 2023 and held it in 1 quarter.
  • Parkman Healthcare Partners's Soleno Therapeutics position peaked at $2.95M in Q3 2023.
  • 76 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.